The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy

Journal of Surgical Oncology

Volumn 107, Issue 6, 2013, Pages 641-645

  Chen, Shi ^a   Feng, Xing Yu ^a   Li, Yuan Fang ^a   Zhao, Bai Wei ^a   Zhou, Zhi Wei ^a   Chen, Ying Bo ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CEA; D2 gastrectomy; gastric cancer; marginally elevated; prognosis

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; GASTRECTOMY; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; STOMACH CANCER; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876416176     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23300     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2000. CA Cancer J Clin 2007; 57: 43-66.
2. Zhan YQ, Li W, Sun XW, et al.: Long-term results of surgical treatment of stomach cancer: Clinical experience of forty years from Sun Yat-sen University Cancer Center. Zhonghua Wai Ke Za Zhi 2005; 43: 1109-1113.
3. Wang W, Li YF, Sun XW, et al.: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer 2010; 29: 923-930.
4. Songun I, Putter H, Kranenbarg EM, et al.: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
5. Sierra A, Regueira FM, Hernandez-Lizoain JL, et al.: Role of the extended lymphadenectomy in gastric cancer surgery: Experience in a single institution. Ann Surg Oncol 2003; 10: 219-226.
6. Wu CW, Hsiung CA, Lo SS, et al.: Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
7. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
8. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
9. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
10. Staab HJ, Anderer FA, Brummendorf T, et al.: Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancer. Br J Cancer 1982; 45: 718-727.
11. Pectasides D, Mylonakis A, Kostopoulou M, et al.: CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997; 20: 348-353.
12. Ohkura H:, Tumor markers in monitoring response to chemotherapy for patients with gastric cancer. Jpn J Clin Oncol 1999; 29: 525-526.
13. Takahashi Y, Takeuchi T, Sakamoto J, et al.: The usefulness of CEA and/or CA 19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study. Gastric Cancer 2003; 6: 142-145.
14. Safi F, Kuhns V, Beger HG:, Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer. Int J Biol Markers 1995; 10: 100-106.
15. Gaspar MJ, Arribas I, Coca MC, et al.: Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 2001; 22: 318-322.
16. Kochi M, Fujii M, Kanamori N, et al.: Evaluation of serum CEA and CA 19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000; 3: 177-186.
17. Yamamoto M, Baba H, Toh Y, et al.: Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol 2007; 133: 471-476.
18. Kim HJ, Lee KW, Kim YJ, et al.: Chemotherapy-induced transient CEA and CA 19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol 2009; 48: 385-390.
19. Sturgeon CM, Duffy MJ, Hofmann BR, et al.: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010; 56: e1-e48.
20. Perkins GL, Slater ED, Sanders GK, et al.: Serum tumor markers. Am Fam Physician 2003; 68: 1075-1082.
21. Schlieman MG, Ho HS, Bold RJ:, Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138: 951-955; discussion 955-956.
22. Yoo CH, Noh SH, Shin DW, et al.: Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242.
23. Bando E, Yonemura Y, Takeshita Y, et al.: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-262.
24. Park SH, Ku KB, Chung HY, et al.: Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas. Cancer Res Treat 2008; 40: 16-21.
25. Wirth T, Soeth E, Czubayko F, et al.: Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp Metastasis 2002; 19: 155-160.
26. Benchimol S, Fuks A, Jothy S, et al.: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-334.
27. Screaton RA, Penn LZ, Stanners CP:, Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 1997; 137: 939-952.
28. Watanabe T, Uchida M, Harada K, et al.: A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1. Gan To Kagaku Ryoho 2007; 34: 605-608.
29. Kimura Y, Imasato M, Yano H, et al.: Paclitaxel-resistant recurrent gastric cancer responsive to docetaxel: A case report. Gan To Kagaku Ryoho 2011; 38: 643-645.